Immunoadsorption therapy in Autoimmune Membranous Nephropathy

• Research type

  Research Study

• Full title

  Phase II trial investigating the safety and feasibility of Peptide GAM Immunoadsorption in anti-PLA2R positive autoimmune membranous nephropathy.

• IRAS ID

  198481

• Contact name

  Sandip Mitra

• Contact email

  sandip.mitra@cmft.nhs.uk

• Sponsor organisation

  Manchester University NHS Foundation Trust

• Clinicaltrials.gov Identifier

  15/0560, WTCRF Number

• Duration of Study in the UK

  1 years, 5 months, 28 days

• Research summary

  Autoimmune Membranous Nephropathy is now understood to be a condition caused by the immune system although the exact mechanism is not completely known. By removing the offending part of the immune system using immunoadsorption we will be able to not only treat the disease but also use the opportunity to better understand the mechanism of disease. This will allow more targeted treatment in the future with less
  complications and side effects.

• REC name

  North West - Greater Manchester West Research Ethics Committee

• REC reference

  16/NW/0560

• Date of REC Opinion

  16 Aug 2016

• REC opinion

  Favourable Opinion